Page 1

Press release CyBio closes short fiscal year with moderate net loss Jena,December17,2009–FollowingtheacquisitionofamajorityshareholdingbyAnalytikJena AGandtheresultingchangeinitsfiscalyear,theCyBioGroup(DeutscheBörse,General Standard,ISINDE005412308)closedtheshortfiscalyearendingSeptember30,2009withlower salesandamoderateconsolidatednetloss.TheJena-basedproviderofsimultaneouspipetting technologiesgeneratedsalesofEUR10.9millionintheninemonthsunderreview,down EUR0.2milliononthesameperiodof2008.TheconsolidatednetlossimprovedtoEUR-0.3 millionbutremainednegative.  “Inthepastfiscalyear,CyBiohashadtomakeimportantdecisionsonitsfuturecoursefollowing theacquisitionbyAnalytikJena,”commentedJensAdomat,CEOofCyBioAG.“Thethreecore itemsofthisprocesswerethestructuralandstrategicreorientationofourCompanyinadifficult economicphase,thedevelopmentofextensivesynergieswithAnalytikJenaandtheadjustment oftheCompany’ssalesandcoststructuretoreflectthechangesinthemarketenvironment.”  Salesofinstrumentsinparticularfailedtomeetexpectationsbysomedistance,fallingby EUR2.2millioncomparedwiththesameperiodofthepreviousyear.Thisdevelopmentwasoffset bythestronggrowthofmorethanEUR2.0millionintheareaofautomationprojects,although thissegmenthaslowermarginsandissubjecttohighvolatility.Therewasalsoanencouraging riseinsalesofconsumablesintheshortfiscalyearfromEUR2.3milliontoEUR2.5million, representinganincreaseof8.7%.  Thesalesgeneratedintheshortfiscalyear2009wereprimarilyconcentratedonthesales subsidiaryCyBioJapanCo.Ltd.andCyBioAGitself.Automationprojectsaccountedforaround EUR2.8millionor25.7%oftotalsalescomparedwithjustEUR0.3millioninthepreviousyear. TheJapanesesalessubsidiaryformedtwoyearsagoagaindoubleditssales,whereastheUSAand UKsalesregionsarefeelingtheimpactoftheeconomicandfinancialcrisistoafargreaterextent. Despitesuccessfullyacquiringnewcustomers,salesatCyBioNELtd.declinedyear-on-year,while thesalessubsidiaryCyBioUSInc.alsosawasharpdownturn. 


TheCompanysignificantlyimproveditsearningssituationthankstothestartoftherestructuring process,thecostreductionsthathavebeeninitiatedand,inparticular,thereversalofprovisions. AtEUR-0.3million,however,CyBioagainrecordedaconsolidatednetloss.Inthepreviousfiscal year,theconsolidatednetlossamountedtoEUR-4.5million.Theoperatingresult(EBIT)forthe periodunderreviewtotaledEUR-0.5million(previousyear:EUR-4.3million)foranEBITmargin of-4.23%.EarningspershareimprovedtoEUR-0.05(previousyear:EUR-0.83).Attheendof theperiod,theGrouphadcashandcashequivalentsofEUR0.8million(previousyear: EUR1.3million).  “Theconsolidatednetlosshasimprovedagainstthepreviousyearthankstotherestructuring measuresthatwereurgentlyrequiredasaresponsetothesharpfallininstrumentsales,aswellas theaforementionedeffectsfromthereversalofprovisions,”continuedAdomat.“Allinall,the shortfiscalyearwasunsatisfactoryduetothedifficultmacroeconomicenvironmentand additionalintegrationrequirementsfollowingtheacquisitionbyAnalytikJenaAG.The problematicliquiditysituationthatemergedmidwaythroughtheyearwasonlyresolvedwiththe assistanceoftheparentgroup.ItwilltakeeveryefforttogetCyBiobackontrack.”  AsofSeptember30,2009,theGrouphad122employees(December31,2008:128).  Contact: CyBioAG GöschwitzerStr.40 07745Jena Phone 03641.351495 Fax 03641.351409 Email:irpr@cybio-ag.com

http://www.pressebox.de/attachments/258240/PM_Jahresabschluss 09_e_171209  

http://www.pressebox.de/attachments/258240/PM_Jahresabschluss 09_e_171209.pdf

Read more
Read more
Similar to
Popular now
Just for you